Measuring Binding Kinetics of Ligands
with Tethered Receptors by Fluorescence Polarization
Complemented with
Total Internal Reflection Fluorescence Microscopy

KWOK Ka Cheung

A thesis submitted in partial fulfillment of the requirements
for the degree of
Doctor of Philosophy

Principal supervisor: Prof CHEUNG Nai Ho

Hong Kong Baptist University

July 2010
Abstract

The study of the binding between estrogen receptors (ER) and their ligands in vitro has long been of interest mainly because of its application in anti-estrogen drug discovery for breast cancer treatment as well as in the screening of environmental contaminants for endocrine disruptors. Binding strength was conventionally quantified in terms of equilibrium dissociation constant ($K_D$). Recently, emphasis is shifting towards kinetics rate constants, and off-rate ($k_{off}$) in particular. This thesis reported a novel method to measure such binding kinetics based on fluorescence polarization complemented with total internal reflection fluorescence (FP-TIRF). It used tethered receptors in a flow cell format. For the first time, the kinetics rate constants of the binding of full-length human recombinant ER$\alpha$ with its standard ligands were measured. $k_{off}$ was found to range from $1.3 \times 10^{-3}$ to $2.3 \times 10^{-3}$ s$^{-1}$. $k_{on}$ ranged from $0.3 \times 10^5$ to $11 \times 10^5$ M$^{-1}$ s$^{-1}$. The method could also be used to screen potential ligands. Motivated by recent findings that ginsenosides might be functional ligands of nuclear receptors, eleven ginsenosides were scanned for binding with ER$\alpha$ and peroxisome proliferator-activated receptor gamma (PPAR$\gamma$). None of the ginsenosides showed significant binding to ER$\alpha$, but Rb1 and 20(S)-Rg3 exhibited significant specific binding with PPAR$\gamma$. 
# Table of Contents

Declaration ............................................................................................................................................ i  
Abstract ............................................................................................................................................. ii  
Acknowledgments ................................................................................................................................ iii  
Table of Contents ................................................................................................................................. iv  
List of Tables ......................................................................................................................................... viii  
List of Figures ....................................................................................................................................... ix  
List of Abbreviations ............................................................................................................................ xiv

Chapter 1   Introduction .........................................................................................................................  1

Chapter 2   Background ..........................................................................................................................  4

  2.1   Receptor ligand interaction ..........................................................................................................  4

     2.1.1 Nuclear Receptor superfamily ............................................................................................  4
     2.1.2 Estrogen receptor structure and function ...........................................................................  5
     2.1.3 Breast cancer and drug discovery ...................................................................................... 10
     2.1.4 Endocrine disruptors and contaminant screening ............................................................. 12
     2.1.5 Peroxisome proliferator-activated receptors .................................................................... 13
     2.1.6 Ginsenosides ...................................................................................................................... 14

  2.2   *In-vitro* binding assays ............................................................................................................... 16

     2.2.1 Mass difference assays ......................................................................................................... 16
     2.2.2 Surface plasmon resonance (SPR) .................................................................................... 16
     2.2.3 Fluorescence assays ............................................................................................................ 18
2.2.4 Total internal reflection fluorescence (TIRF) ...................... 19

2.2.5 Total internal reflection with fluorescence correlation spectroscopy (TIR-FCS) ........................................................................... 20

2.2.6 Total internal reflection with fluorescence photobleaching recovery (TIR-FPR) ........................................................................ 21

2.2.7 Total internal reflection with reflectance interferometry (TIR-RIf) ..................................................................................... 22

2.2.8 Fluorescence polarization (FP) .................................................. 23

2.2.9 Free probes versus tethered probes ........................................ 24

Chapter 3 Methods ........................................................................... 26

3.1 FP-TIRF setup ............................................................................. 26

3.2 Setup optimization and calibration ............................................. 27

3.3 Flow cell fabrication and fluidics ................................................. 29

3.3.1 Flow cell fabrication .............................................................. 30

3.3.2 Fluidics ................................................................................ 31

3.4 Channel surface preparation ...................................................... 32

3.4.1 Coating with PEG ............................................................... 32

3.4.2 Immobilization of primary and secondary antibody ............. 33

3.4.3 Receptor preparation and tethering ....................................... 34

3.5 Ligand preparation ................................................................... 36

3.6 Program for real-time data capture and display ....................... 36

3.7 Data runs ................................................................................ 38
3.7.1   Kinetics data capture for surface tethered receptors ............ 38
3.7.2   Kinetics data capture for free receptors and ligands in solution .. 39
3.7.3   Screening ginsenosides for binding with nuclear receptors ...... 40
3.8     Data analysis – From fluorescence anisotropy to bound fraction ...... 41
3.9     Kinetics modeling ................................................................. 43
3.10    Rapid mixing assumption .................................................. 44

Chapter 4  Results and discussion ................................................. 46
4.1     Characterization of the FP-TIRF setup .................................. 47
  4.1.1   Correcting for // and \ perpendicular arm imbalance ........... 47
  4.1.2   Monitoring [F] .............................................................. 48
  4.1.3   Consistency of FP and TIRF ........................................... 48
4.2     Characterization of each tether link ...................................... 51
  4.2.1   Strength and specificity of tether ..................................... 52
  4.2.2   Tethering preserved receptor function ............................. 57
  4.2.3   Tethering preserved the random orientation of μ ................ 59
4.3     Binding kinetics of the fluorescent ligand with ERα ................ 62
4.4     Justify rapid mixing assumption ........................................ 68
4.5     Binding kinetics of nonfluorescent ligands with ERα ............... 72
4.6     Positive and negative controls ......................................... 78
4.7     Screening ginsenosides for ERα binding .............................. 80
4.8     Screening ginsenosides for PPARγ binding ........................... 82
4.9     Binding affinity and chemical structure ............................... 85
Chapter 5  Conclusion ................................................................. 91

List of References ................................................................. 94

Curriculum Vitae ................................................................. 100